Among the 87 patients with breast cancer, there were 12 patients (13.8%) with luminal A, 22 patients (25.3%) with luminal B, 23 patients (26.4%) with luminal B HER2 type, 9 patients (10.3%) with triple negative type, and 16 patients (18.3%) with HER2 type. This evidence concerns the gene ERBB2 and breast cancer.